Visiopharm

Visiopharm® is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no less than eight diagnostic algorithms cleared under IVDR for EU customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows.

Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company's headquarters are located in Denmark's Medicon Valley, with offices in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.

https://imageanalysis.visiopharm.com/knowledge/about-us

Applications by this vendor

ER APP, Breast Cancer

CE | ER

The ER APP automatically analyses whole slide images of breast cancer tissue stained by estrogene receptor and provide objective results for the % of positive cells, H-score and Allred score.

Ki-67 APP, Breast Cancer

CE | KI67

Ki-67 APP analyzes the whole slide, automatically identifying patient vs control tissue, detects nuclei in the invasive tumor only and returning a proliferation index for the entire tumor region. It can be combined with the Hot Spot detection APP.

HER2 APP, Breast Cancer

CE | HER2

HER2 APP analyses the whole slide, using the Visiopharm's HER2-Connect algorithm to asses the membrane completeness, outputting a continious connectivity score and the discrete 0, 1+, 2+, and 3+ score.

PD-L1 APP, NSCLC

CE | PD-L1

PD-L1 APP analyzes the whole slide, automatically identifying patient vs control tissue, detecting nuclei in the invasive tumor and calculating the Tumor Positive Score (TPS) along with a Heatmap of the TPS.

PR APP, Breast Cancer

CE | PR

The PR APP automatically analyses whole slide images of breast cancer tissue stained by progesterone receptor and provide objective results for the % of positive cells, H-score and Allred score.

Metastasis Detection, AI

CE | H&E

The APP automtically analyses whole slides to detect micro- and macro metastisis that are not easily noticed in lymph nodes associated with breast and colon adenocarcinoma, stained with H&E. Detected areas are categories by likelihood.